Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Malignant mixed germ cell tumor of ovary presenting as advanced disease in an adolescent girl
1Department of Radiotherapy, Regional Institute of Medical Science, Imphal, India
2Department of Obstetrics and Gynaecology, Regional Institute of Medical Sciences, Imphal, India
*Corresponding Author(s): V. Amirthalingam E-mail: venkydr85@gmail.com
Mixed germ cell tumors are very rare in young females. Patient survival, preservation of ovarian function and fertility are becoming an important issue. A locally advanced (III), bulky malignant mixed germ cell tumour in a 12-year-old girl presented to the Department of Radiotherapy, Regional Institute of Medical Sciences, Imphal, Manipur, in January 2011 with abdominal distension for one month. On physical examination, there was a large lower abdominal mass approximately 16×14 cm2 . Abdominal and pelvic CTs showed a lobulated 19×15×10 cm soft tissue attenuation mass lesion in the pelvis extending superoanteriorly to supra-umbilical area. Laboratory investigations revealed increased serum LDH (4,245 IU/L) and serum β-hCG (105.4 mIU/ml). Ultrasonography (USG)-guided fine needle aspiration cytology (FNAC) from left ovarian mass was suggestive of malignant germ cell tumour. In view of bulky and advanced stage, patient was administered four cycles of neoadjuvant chemotherapy (inj. ifosphamide 1,440 mg, inj. etoposide 90 mg, inj. cisplatin 24 mg for D1-5, four weekly) followed by left salpingo-oophorectomy with wedge biopsy of right ovary and partial omentectomy, and another two cycles of adjuvant chemotherapy with same regimen. Biopsy tissue histopathology report also confirmed mixed germ cell tumour. Patient was kept on regular follow-up and she has been disease-free for the last four years. The present authors' treatment policy in such bulky and advanced tumor in adolescents is effective.
Dysgerminomas; Non- dysgerminomas; Mixed germ cell tumor; Gonadoblastoma.
V. Amirthalingam, T.d. Sharma, P.c. Rai, T.t. Singh, K.p. Devi. Malignant mixed germ cell tumor of ovary presenting as advanced disease in an adolescent girl. European Journal of Gynaecological Oncology. 2016; 37(5): 750-752. doi: 10.12892/ejgo3179.2016
[1] Gershenson D.M., Del Junco G., Rutledge F.N.: “Mixed germ cell tumours of ovary”. Obstet. Gynecol., 1984, 64, 200.
[2] Kurman R.J., Norris H.J.: “Malignant mixed germ cell tumours of the ovary: A clinical & pathologic analysis of 30 cases”. Obstet. Gynecol., 1976, 48, 579.
[3] Kurman RJ, Norris H.J.: “Malignant germ cell tumours of ovary”. Hum. Pathol., 1977, 8, 551.
[4] Zuntova A., Sumerauer D.: “Mixed germ cell tumours of the ovary in childhood and adolescence”. Cesk. Patol., 2004, 40, 92. [Article in Czech]
[5] Yilmaz F., Gul T., Uzunlar A.K.: “Malignant ovarian germ cell tumours: analysis of 32 cases”. Eur. J. Gynaecol. Oncol., 2003, 24, 569.
[6] Ayhan A., Tuncer Z.S., Yanik F.: “Malignant germ cell tumours of the ovary:Hacettepe hospital experience”. Acta Obstet. Gynecol., 1995, 74, 384.
[7] Gershenson D.M.: “Management of ovarian germ cell tumors”. J. Clin. Oncol., 2007, 25, 2938.
[8] Segelov E., Campbell J., Ng M., Tattersall M., Rome R., Free K., et al.: “Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience”. J. Clin. Oncol.,1994, 12, 378.
[9] Dimopoulos M.A., Papadopoulou M., Andreopoulou E., Papadimitriou C., Pavlidis N., Aravantinos G., et al.: “Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatinbased chemotherapy: a Hellenic Cooperative Oncology Group study”. Gynecol. Oncol., 1998, 70, 70.
[10] Lu K.H., Gershenson D.M.: “Update on the management of ovarian germ cell tumors”. J. Reprod. Med., 2005, 50, 417.
[11] Kumar L., Talukdar S., Hariprasad R., Gupta A., Mookerjee A., Kumar S., et al.: “Is there a place for neoadjuvant chemotherapy inthe management of advanced malignant germ cell tum ors of ovary?J. Clin. Oncol., 2011, 29, 5079
[12] Maheshwari A., Gupta S., Tongaonkar H.B.: “Malignant ovarian germ cell tumours: long-term treatment outcome”. J. Clin. Oncol.,2005, 23, 5132.
Top